Akt is a molecular target for signal transduction therapy in brain ischemic insult

Journal of Pharmacological Sciences

Volumn 92, Issue 4, 2003, Pages 317-327

  Fukunaga, Kohji ^a   Kawano, Takayuki ^b  

^a TOHOKU UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Akt; Brain ischemia; Neuroprotection; Signal transduction; Vanadate

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CALCIUM; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LITHIUM SALT; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NITRIC OXIDE SYNTHASE; ORTHOVANADIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; RECOMBINANT BRAIN DERIVED NEUROTROPHIC FACTOR; RECOMBINANT ERYTHROPOIETIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; VANADATE SODIUM; VANADIUM DERIVATIVE;

APOPTOSIS; BRAIN INJURY; BRAIN ISCHEMIA; CALCIUM CELL LEVEL; CELL DEATH; CELL SURVIVAL; CEREBROVASCULAR ACCIDENT; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; HIPPOCAMPUS; HUMAN; HUNTINGTON CHOREA; MOLECULAR DYNAMICS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN PHOSPHORYLATION; PYRAMIDAL NERVE CELL; REVIEW; SEIZURE; SIGNAL TRANSDUCTION;

EID: 0042734922     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.92.317     Document Type: Review

References (118)

1. Kirino T. Delayed neuronal death in the gerbil hippocampus following ischemia. Brain Res. 1982;239:57-69.
2. Martin RL, Lloyd HG, Cowan AI. The early events of oxygen and glucose deprivation: Setting the scene for neuronal death? Trends Neurosci. 1994;17:251-257.
3. Katsura K, Kristian T, Siesjo BK. Energy metabolism, ion homeostasis, and cell damage in the brain. Biochem Soc Trans. 1994;22:991-996.
4. 2+/calmodulin-dependent protein kinase II and calcineurin in the hippocampus of rat brain after transient forebrain ischemia. J Neurochem. 1992;58:1798-1809.
5. O'Neill LA, Kaltschmidt C. NF-kappa B: A crucial transcription factor for glial and neuronal cell function. Trends Neurosci. 1997;20:252-258.
6. Ruscher K, Isaev N, Trendelenburg G, et al. Induction of hypoxia inducible factor 1 by oxygen glucose deprivation is attenuated by hypoxic preconditioning in rat cultured neurons. Neurosci Lett. 1998;254:117-120.
7. Iadecola C, Salkowski CA, Zhang F, et al. The transcription factor interferon regulatory factor 1 is expressed after cerebral ischemia and contributes to ischemic brain injury. J Exp Med. 1999;189:719-727.
8. Planas AM, Soriano MA, Berruezo M, et al. Induction of Stat3, a signal transducer and transcription factor, in reactive microglia following transient focal cerebral ischaemia. Eur J Neurosci. 1996;8:2612-2618.
9. Rothwell NJ, Hopkins SJ. Cytokines and the nervous system II: Actions and mechanisms of action. Trends Neurosci. 1995;18:130-136.
10. Forster C, Clark HB, Ross ME, Iadecola C. Inducible nitric oxide synthase expression in human cerebral infarcts. Acta Neuropathol. 1999;97:215-220.
11. Iadecola C. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci. 1997;20:132-139.
12. Iadecola C, Zhang F, Casey R, Nagayama M, Ross ME. Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J Neurosci. 1997;17:9157-9164.
13. Nogawa S, Zhang F, Ross ME, Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci. 1997;17:2746-2755.
14. Staal SP, Hartley JW, Rowe WP. Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. Proc Natl Acad Sci USA. 1977;74:3065-3067.
15. Staal SP, Hartley JW. Thymic lymphoma induction by the AKT8 murine retrovirus. J Exp Med. 1988;167:1259-1264.
16. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: Amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA. 1987;84:5034-5037.
17. Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science. 1991;254:274-277.
18. Coffer PJ, Woodgett JR. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem. 1991;201:475-481.
19. Jones PF, Jakubowicz T, Pitossi FJ, Mauer F, Hemmings BA. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci USA. 1991;88:4171-4175.
20. Konishi H, Kuroda S, Tanaka M, et al. Molecular cloning and characterization of a new member of the RAC protein kinase family: Association of the pleckstrin homology domain of three types of RAC protein kinase with protein kinase C subspecies and beta gamma subunits of G proteins. Biochem Biophys Res Commun. 1995;216:526-534.
21. Bellocosa A, Franke TF, Gonzalez-Portal ME, et al. Structure, expression and chromosomal mapping of c-akt: Relationship to v-akt and its implications. Oncogene. 1993;8:745-754.
22. Hemmings BA. Akt signaling: Linking membrane events to life and death decisions. Science. 1997;275:628-630.
23. Murga C, Laguinge L, Wetzker R, Cuadrado A, Gutkind JS. Activation of Akt/protein kinase B by G protein-coupled receptors. J Biol Chem. 1998;273:19080-19085.
24. Krugmann S, Hawkins PT, Pryer N, Braselmann S. Characterizing the interactions between the two subunits of the p110/p100 phospoinositide 3-kinase and their role in the activation of this enzyme by G subunits. J Biol Chem. 1999;274:17152-17158.
25. Datta K, Bellacosa A, Chan TO, Tsichlis PN. Akt is a direct target of the phosphatidylinositol 3-kinase. J Biol Chem. 1996;271:30835-30839.
26. Andjelkovic M, Aless DR, Meier R, et al. Role of translocation in the activation and function of protein kinase B. J Biol Chem. 1997;272:31515-31524.
27. Kohn AD, Takeuchi F, Roth RA. Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. J Biol Chem. 1996;271:21920-21926.
28. Alessi DR, Andjelkovic M, Caudwell BF, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996;15:6541-6551.
29. Alessi DR, James SR, Downes P, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B. Curr Biol. 1997;7:261-269.
30. Stephens L, Anderson K, Stokoe D, et al. Protein kinase B kinases that mediate phosphatidyleinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science. 1998;279:710-714.
31. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/Akt by integrin-linked kinase. Proc Natl Acad Sci USA. 1998;95:11211-11216.
32. Yano S, Tokumitsu H, Soderling TR. Calcium promotes cell survival through CaM-K kinase activation of the protein kinase B pathway. Nature. 1998;396:584-587.
33. Hajduch E, Alessi DR, Hemmings BA, Hundal HS. Constitutive activation of protein kinase B alpha by membrane targeting promotes glucose and system A amino acid transport, protein synthesis, and inactivation of glycogen synthase kinase 3 in L6 muscle cells. Diabetes. 1998;47:1006-1013.
34. Tanti JF, Grillo S, Gremeaux T, Coffer PJ, Van Obberghen E, Le Marchand-Brustel Y. Potential role of protein kinase B in glucose transporter 4 translocation in adipocytes. Endocrinology. 1997;138:2005-2010.
35. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785-789.
36. Deprez J, Vertommen D, Alessi DR, Hue L, Rider MH. Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. J Biol Chem. 1997;272:17269-17275.
37. Kimball SR, Vary TC, Jefferson LS. Regulation of protein synthesis by insulin. Annu Rev Physiol. 1994;56:321-348.
38. Azpiazu I, Saltiel AR, DePaoli-Roach AA, Lawrence JC. Regulation of both glycogen synthase and PHAS-I by insulin in rat skeletal muscle involves mitogen-activated protein kinase-independent and rapamycin-sensitive pathways. J Biol Chem. 1996;271:5033-5099.
39. Beretta L, Gingras AC, Svitkin YV, Hall MN, Sonenberg N. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J. 1996;15:658-664.
40. Fadden P, Haystead TA, Lawrence JC Jr. Identification of phosphorylation sites in the translational regulator, PHAS-I, that are controlled by insulin and rapamycin in rat adipocytes. J Biol Chem. 1997;272:10240-10247.
41. Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 1995;376:599-602.
42. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-241.
43. +-induced apoptosis of cerebellar granule neurons. Brain Res Dev Brain Res. 1997;101:197-206.
44. Crowder RJ, Freeman RS. Phosphatidylinositol 3-kinase and Akt protein kinase are necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons. J Neurosci. 1998;18:2933-2943.
45. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation. 2000;101:660-667.
46. Miao W, Luo Z, Kitsis RN, Walsh K. Intracoronary, adenovirus-mediated Akt gene transfer in heart limits infarct size following ischemia-reperfusion injury in vivo. J Mol Cell Cardiol. 2000;32:2397-2402.
47. Jonassen AK, Sack MN, Mjos OD, Yellon DM. Myocardial protection by insulin at reperfusion required early administration and is mediated via Akt p70s6 kinase cell-survival signaling. Circulation Res. 2001;89:1191-1198.
48. Matsui T, Tao J, Del Monte F, et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation. 2001;104:330-335.
49. Yamashita K, Kajstura J, Discher DJ, et al. Rerperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts overexpressing insulin-like growth factor-1. Circulation Res. 2001;88:609-614.
50. Ouyang YB, Tan Y, Comb M, et al. Survival- and death-promoting events after transient cerebral ischemia: Phosphorylation of Akt, release of cytochrome C, and activation of caspase-like proteases. J Cereb Blood Flow Metab. 1999;19:1126-1135.
51. Kawano T, Fukunaga K, Takeuchi Y, et al. Neuroprotective effect of sodium orthovanadate on delayed neuronal death after transient forebrain ischemia in gerbil hippocampus. J Cereb Blood Flow Metab. 2001;21:1268-1280.
52. Jin K, Mao XO, Batteur SP, Mceachron E, Leahy A, Greenberg DA. Caspase-3 and the regulation of hypoxic neuronal death by vascular endothelial growth factor. Neuroscience. 2001;108: 351-358.
53. Noshita N, Lewen A, Sugawara T, Chan PH. Evidence of phosphorylation of Akt and neuronal survival after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab. 2001;21:1442-1450.
54. Shibata M, Yamawaki T, Sasaki T, et al. Upregulation of Akt phosphorylation at the early stage of middle cerebral artery occlusion in mice. Brain Res. 2002;942:1-10.
55. Kitagawa H, Warita H, Sasaki C, et al. Immunoreactive Akt, PI3-K and ERK protein kinase expression in ischemic rat brain. Neurosci Lett. 1999;274:45-48.
56. Yano S, Morioka M, Fukunaga K, et al. Activation of Akt/protein kinase B contributes to induction of ischemic tolerance in the CA1 subfield of gerbil hippocampus. J Cereb Blood Flow Metab. 2001;21:351-360.
57. Lizcano JM, Morrice N, Cohen P. Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, Ser155. Biochem J. 2000;349:547-557.
58. Tan Y, Demeter MR, Ruan H, Comb MJ. BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival. J Biol Chem. 2000;275:25865-25869.
59. Masters SC, Yang H, Datta SR, Greenberg ME, Fu H. 14-3-3 inhibits Bad-induced cell death through interaction with serine-136. Mol Pharmacol. 2001;60:1325-1331.
60. 2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science. 1999;284:339-343.
61. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91:479-489.
62. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell. 1997;90:405-413.
63. Bratton SB, Walker G, Srinivasula SM, et al. Recruitment, activation and retention of caspases-9 and -3 by Apaf-1 apoptosome and associated XIAP complexes. EMBO J. 2001;20:998-1009.
64. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998;282:1318-1321.
65. Biggs III WH, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA. 1999;96:7421-7426.
66. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857-868.
67. Nakae J, Barr V, Accili D. Differential regulation of gene expression by insulin and IGF-1 receptors correlates with phosphorylation of a single amino acid residue in the forkhead transcription factor FKHR. EMBO J. 2000;19:989-996.
68. Lin K, Dorman JB, Rodan A, Kenyon C. daf-16: An HNF-3/forkhead family member that can function to double the lifespan of Caenorhabditis elegans. Science. 1997;278:1319-1322.
69. Dijkers PF, Medema RH, Lammers JWJ, Koenderman L, Coffer PJ. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHRL-1. Curr Biol. 2000;10:1201-1204.
70. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers W. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol. 2000;20:8969-8982.
71. Kawano T, Morioka M, Yano S, et al. Decreased Akt activity is associated with activation of forkhead transcription factor after transient forebrain ischemia in gerbil hippocampus. J Cereb Blood Flow Metab. 2002;22:926-934.
72. Du K, Montminy M. CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem. 1998;273:32377-32379.
73. Shieh PB, Hu SC, Bobb K, Timmusk T, Ghosh A. Identification of a signaling pathway involved in calcium regulation of BDNF expression. Neuron. 1998;20:727-740.
74. 2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron. 1998;20:709-726.
75. Romashkova JA, Makarov SS. NF-κB is a target of Akt in anti-apoptotic PDGF signalling. Nature. 1999;401:86-90.
76. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-κB activation by tumor necrosis factor requires the Akt serine-theorine kinase. Nature. 1999;401:82-85.
77. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci USA. 1997;94:10057-10062.
78. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev. 1999;13:382-387.
79. Han BH, Holtzman DM. BDNF protects the neonatal brain from hypoxic-ischemic injury in vivo via the ERK pathway. J Neurosci. 2000;20:5775-5781.
80. Elberg G, Li J, Schechter Y. Vanadium activates or inhibits receptor and non-receptor protein tyrosine kinases in cell-free experiments, depending on its oxidation state. Possible role of endogenous vanadium in controlling cellular protein tyrosine kinase activity. J Biol Chem. 1994;269:9521-9527.
81. Fantus IG, Ahmad F, Deragon G. Vanadate augments insulin-stimulated insulin receptor kinase activity and prolongs insulin action in rat adipocytes. Evidence for transduction of amplitude of signaling into duration of response. Diabetes. 1994;43:375-383.
82. 2 and vanadate stimulate protein tyrosine phosphorylation in intact cells. J Biol Chem. 1990;265:2896-2902.
83. Posner BI, Faure R, Burgess JW, et al. Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J Biol Chem. 1994;269:4596-4604.
84. Shechter Y. Insulin-mimetic effects of vanadate. Possible implications for future treatment of diabetes. Diabetes. 1990;39:1-5.
85. Shisheva A, Schechter Y. Mechanism of pervanadate stimulation and potentiation of insulin-activated glucose transport in rat adipocytes: Dissociation from vanadate effect. Endocrinology. 1993;133:1562-1568.
86. Sakurai H, Kojima Y, Yoshikawa Y, Kawabe K, Yasui H. Antidiabetic vanadium (IV) and zinc (II) complexes. Coordination Chem Rev. 2002;226:187-198.
87. Yasui H, Tamura A, Takino T, Sakurai H. Structure-dependent metallokinetics of antidiabetic vanadyl-picolinate complexes in rats: Studies on solution structure, insulinomimetic activity, and metallokinetics. J Inorganic Biochem. 2002;91:327-338.
88. Bevan AP, Burgess JW, Yale JF, et al. In vivo insulin mimetic effects of pV compounds: Role for tissue targeting in determining potency. Am J Physiol. 1995;268:E60-E66.
89. McNeill JH, Yuen VG, Dai S, Orvig C. Increase potency of vanadium using organic ligands. Mol Cell Biochem. 1995;153:175-180.
90. Brichard SM, Okitolonda W, Henquin JC. Long term improvement of glucose homeostasis by vanadate treatment in diabetic rats. Endocrinology. 1988;123:2048-2053.
91. Cohen N, Halberstam M, Shilimovich P, Chang CJ, Shamoon H, Rossetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin dependent diabetes mellitus. J Clin Invest. 1995;95:2501-2509.
92. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR. In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus. Mol Cell Biochem. 1995;153:217-231.
93. Chin LS, Murray SF, Harter DH, Doherty PF, Singh SK. Sodium vanadate inhibits apoptosis in malignant glioma cells: A role for Akt/PKB. J Biomed Sci. 1999;6:213-218.
94. Totpal K, Agarwal S, Aggarwal BB. Phosphatase inhibitors modulate the growth-regulatory effects of human tumor necrosis factor on tumor and normal cells. Cancer Res. 1992;52:2557-2562.
95. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell. 1995;80:285-291.
96. Figiel I, Kaczmarek L. Orthovanadate induces cell death in rat dentate gyrus primary culture. Neuroreport. 1997;8:2465-2470.
97. Gluckman P, Klempt N, Guan J, et al. A role for IGF-1 in the rescue of CNS neurons following hypoxic-ischemic injury. Biochem Biophys Res Commun. 1992;182:593-599.
98. Guan J, Williams C, Gunning M, Mallard C, Gluckman P. The effects of IGF-1 treatment after hypoxic-ischemic brain injury in adult rats. J Cereb Blood Flow Metab. 1993;13:609-616.
99. Tagami M, Ikeda K, Nara Y. et al. Insulin-like growth factor-1 attenuates apoptosis in hippocampal neurons caused by cerebral ischemia and reperfusion in stroke-prone spontaneously hypertensive rats. Lab Invest. 1997;76:613-617.
100. Wang JM, Hayashi T, Zhang WR, Sakai K, Shiro Y, Abe K. Reduction of ischemic brain injury by topical application of insulin-like growth factor-1 after transient middle cerebral artery occlusion in rats. Brain Res. 2000;859:381-385.
101. Zhu CZ, Auer RN. Intraventricular administration of insulin and IGF-1 in transient cerebral ischemia. J Cereb Blood Flow Metab. 1994;14:237-242.
102. Chalecka-Franaszek E, Chuang D-M. Lithium activates the serine/threonine kinase Akt-1 and suppress glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA. 1999;96:8745-8750.
103. + deprivation in cerebeller granule cells. J Neurochem. 2001;78:199-206.
104. Nonaka S, Chuang DM. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport. 1998;9:2081-2084.
105. Wei H, Qin ZH, Senatorov VV, et al. Lithium suppress excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience. 2001;106:603-612.
106. Marti HH, Wenger RH, Rivas LA, et al. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci. 1996;8:666-676.
107. Juul SE, Anderson DK, Christensen RD. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res. 1998;43:40-49.
108. Ruscher K, Freyer D, Karsch M, et al. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: Evidence from an in vitro model. J Neurosci. 2002;22:10291-10301.
109. Bernaudin M, Marti HH, Roussel S, et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab. 1999;19:643-651.
110. Sirén AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA. 2001;98:4044-4049.
111. Chong ZZ, Kang JQ, Maiese K. Hematopoietic factor erythropoietin foster neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab. 2002;22:503-514.
112. Digicarylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signaling cascades. Nature. 2001;412:641-647.
113. Ren JM, Finklestein SP. Time window of infarct reduction by intravenous basic fibroblast growth factor in focal cerebral ischemia. Eur J Pharmacol. 1997;327:11-16.
114. Li Q, Stephenson D. Postischemic administration of basic fibroblast growth factor improves sensorimotor function and reduces infarct size following permanent focal cerebral ischemia in the rat. Experimental Neurol. 2002;177:531-537.
115. Ay I, Sigimori H, Finklestein SP. Intravenous basic fibroblast growth factor (bFGF) decreases DNA fragmentation and prevents downregulation of Bcl-2 expression in the ischemic brain following middle cerebral artery occlusion in rats. Brain Res Mol Brain Res. 2001;87:71-80.
116. Schabitz WR, Sommer C, Zoder W, Kiessling M, Schwaninger M, Schwab S. Intravenous brain-derived neurotrophic factor reduces infarct size and ounterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia. Stroke. 2000;31:2212-2217.
117. Zhang Y, Pardridge WM. Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. Brain Res. 2001;889:49-56.
118. Beilharz EJ, Russo VC, Butler G, et al. Co-ordinated and cellular specific of the IGF/IGFBP axis in the brain following hypoxic-ischemic injury. Brain Res Mol Brain Res. 1998;59:119-134.